Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Anti-PEG antibodies have been reported to mediate the accelerated clearance of PEG-conjugated proteins and liposomes, all of which contain methoxyPEG (mPEG). The goal of this research was to assess the role of the methoxy group in the immune responses to mPEG conjugates and the potential advantages of replacing mPEG with hydroxyPEG (HO-PEG). Rabbits were immunized with mPEG, HO-PEG, or t-butoxyPEG (t-BuO-PEG) conjugates of human serum albumin, human interferon-α, or porcine uricase as adjuvant emulsions. Assay plates for enzyme-linked immunosorbent assays (ELISAs) were coated with mPEG, HO-PEG, or t-BuO-PEG conjugates of the non-cross-reacting protein, porcine superoxide dismutase (SOD). In sera from rabbits immunized with HO-PEG conjugates of interferon-α or uricase, the ratio of titers of anti-PEG antibodies detected on mPEG-SOD over HO-PEG-SOD ("relative titer") had a median of 1.1 (range 0.9-1.5). In contrast, sera from rabbits immunized with mPEG conjugates of three proteins had relative titers with a median of 3.0 (range 1.1-20). Analyses of sera from rabbits immunized with t-BuO-PEG-albumin showed that t-butoxy groups are more immunogenic than methoxy groups. Adding Tween 20 or Tween 80 to buffers used to wash the assay plates, as is often done in ELISAs, greatly reduced the sensitivity of detection of anti-PEG antibodies. Competitive ELISAs revealed that the affinities of antibodies raised against mPEG-uricase were c. 70 times higher for 10 kDa mPEG than for 10 kDa PEG diol and that anti-PEG antibodies raised against mPEG conjugates of three proteins had >1000 times higher affinities for albumin conjugates with c. 20 mPEGs than for analogous HO-PEG-albumin conjugates. Overall, these results are consistent with the hypothesis that antibodies with high affinity for methoxy groups contribute to the loss of efficacy of mPEG conjugates, especially if multiply-PEGylated. Using monofunctionally activated HO-PEG instead of mPEG in preparing conjugates for clinical use might decrease this undesirable effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was found that the methoxy group of the mPEG-protein contributed to a significantly higher immune response than that of hydroxy group of HO-PEG.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Ansar Ahmed, S., Gogal, R. M., & Walsh, J. E. (1994) · Journal of Immunological Methods · doi:10.1016/0022-1759(94)90396-4 · Cited by 1,359
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y., Miyazono, K., Urabe, A., & Takaku, F. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041400219 · Cited by 784
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
FDA-approved poly(ethylene glycol)–protein conjugate drugs
Alconcel, S. N. S., Baas, A. S., & Maynard, H. D. (2011) · Polymer Chemistry · doi:10.1039/c1py00034a · Cited by 643
Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., van der Meer, J. W. M., Corstens, F. H. M., & Boerman, O. C. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35391-1 · Cited by 607
Research works printed but not linked: 4
- Środa K., 2005, Cell. Mol. Biol. Lett., 10, 37
- Porstmann B., 1981, J. Clin. Chem. Clin. Biochem., 19, 435
- Behr-Gross M.-E., 2007, Pharmeuropa Bio., 2007, 49
- Booth C., 2009, Biologics, 3, 349
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
“Antibodies preferentially bound to the PEG backbone when the end functional group was a hydroxyl, and with lesser affinity than binding to methoxy functionalized PEG conjugates [108, 109].”
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
“[154] Likewise, hydroxyl-PEG conjugated to porcine uricase exhibited lower immunogenicity compared with mPEG.[155] Another suggested strategy is administration of short oligomers of PEG prior to the PEGylated drug to avoid formation of immune complexes.”
BackgroundEffects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery
Shi, L., Zhang, J., Zhao, M., Tang, S., Cheng, X., Zhang, W., Li, W., Liu, X., Peng, H., & Wang, Q. (2021) · Nanoscale · doi:10.1039/d1nr02065j · Cited by 808
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
“, the results suggested that hydrophobicity of the PEG endgroup has a notable effect on the conjugate immunogenicity and antigenicity [54].”
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., & Richette, P. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.720969 · Cited by 587
“All currently approved PEGylated therapeutic products contain methoxy-PEG (mPEG) [30,31].”
BackgroundChen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
PEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
“[106], in animal experiment (rabbits), examined the Sci.”
BackgroundAnti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine
Ju, Y., Lee, W. S., Pilkington, E. H., Kelly, H. G., Li, S., Selva, K. J., Wragg, K. M., Subbarao, K., Nguyen, T. H. O., Rowntree, L. C., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04543 · Cited by 372
Yang, Q., Jacobs, T. M., McCallen, J. D., Moore, D. T., Huckaby, J. T., Edelstein, J. N., & Lai, S. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03437 · Cited by 370
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
“In addition, some studies have shown that methylation of the methoxy group on PEG conjugates to eliminate the anionic group can dramatically reduce the immune response [51, 52].”
BackgroundThe Immunogenicity of Polyethylene Glycol: Facts and Fiction
Schellekens, H., Hennink, W. E., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1067-7 · Cited by 340
Improvement of drug safety by the use of lipid-based nanocarriers
Lim, S. B., Banerjee, A., & Önyüksel, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.002 · Cited by 324
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Zhang, P., Sun, F., Tsao, C., Liu, S., Jain, P., Sinclair, A., Hung, H.-C., Bai, T., Wu, K., & Jiang, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512465112 · Cited by 316
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“Anti-PEG IgM and IgG can bind to four or five repeating oxyethylene units of the PEG backbone 66 ; moreover, PEG end-group hydrophobicity increases immunogenicity 60 , suggesting the presence of anti-PEG antibodies that recognize the hydrophobic parts in PEG derivatives.”
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
“1) The type of PEG’s terminal group and 2) the shedding rate of PEGylated lipids from LNPs [65-67].”
BackgroundPotential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.015 · Cited by 267
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4500 · Cited by 266
Magnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Mima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H., & Ishida, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00144 · Cited by 209
Kierstead, P. H., Okochi, H., Venditto, V. J., Chuong, T. C., Kivimae, S., Fréchet, J. M. J., & Szoka, F. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.023 · Cited by 210
“A number of factors can alter or inhibit the ABC effect, including dose size,[15] therapeutic payload,[16] administration regimen,[13] and even PEG end-groups.[17] Still, many materials can initiate the ABC effect, and patients who have been previously exposed to PEG may exhibit anti-PEG IgM.”
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future
Ilinskaya, A. N., & Dobrovolskaia, M. A. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.01.005 · Cited by 209
“The hydrophobicity of PEG terminal groups is thought to be an important antigenicity factor because hydroxyterminated PEG has been shown to be less antigenic than methoxy-PEG, which, in turn, was shown to be less antigenic than t-butoxy-PEG (Sherman et al., 2012; Saifer et al., 2014).”
BackgroundToxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review
Shiraishi, K., & Yokoyama, M. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1590126 · Cited by 208
Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
Huo, D., Jiang, X., & Hu, Y. (2020) · Advanced Materials · doi:10.1002/adma.201904337 · Cited by 205
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
Ju, Y., Carreño, J. M., Simon, V., Dawson, K., Krammer, F., & Kent, S. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00825-x · Cited by 201
Szebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., Barenholz, Y., Crommelin, D. J. A., & Dobrovolskaia, M. A. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01071-x · Cited by 165
Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins
Zhang, F., Liu, M.-R., & Wan, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00661 · Cited by 157
Revealing the Immunogenic Risk of Polymers
Li, B., Yuan, Z., Hung, H., Ma, J., Jain, P. R., Tsao, C., Xie, J., Zhang, P., Lin, X., Wu, K., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201808615 · Cited by 146
Saifer, M. G. P., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Sherman, M. R. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.014 · Cited by 109
“…animals or patients with mPEG conjugates of various roteins, red blood cells, liposomes or adenoviruses has been docuented by several independent research groups (Armstrong, 2009; heng et al., 2012; Ganson et al., 2006; Richter and Åkerblom, 1983; herman et al., 2012a,b; Shimizu et al., 2012).”
Self-citationThe Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System
Makharadze, D., del Valle, L. J., Katsarava, R. D., & Puiggalí, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073102 · Cited by 135
Moncalvo, F., Martinez Espinoza, M. I., & Cellesi, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00089 · Cited by 105
Prakash, S., Tomaro-Duchesneau, C., Saha, S., Kahouli, & Malhotra, M. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s43683 · Cited by 110
“60 Moreover, nanoparticle size has a role in ABC regardless of PEG density and chain length.”
Luo, X., Hou, L., Liang, L., Dong, G., Shen, S., Zhao, Z., Gong, C. X., Li, Y., Du, M., Su, Z., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0905 · Cited by 101
Antibodies against polyethylene glycol in human blood: A literature review
Lu, H., Wang, Z., Wei, X., Shi, J., & Li, C. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106678 · Cited by 113
Fu, S., Zhu, X., Fanghua, H., & Chen, X. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081074 · Cited by 125
“Sherman et al. [29] re-ported that APAs generated by hydroxy-PEG-conjugated proteins displayed similar affinity for methoxy-PEG and hydroxy-PEG.”
Polypeptides with High Zwitterion Density for Safe and Effective Therapeutics
Zhang, P., Jain, P., Tsao, C., Yuan, Z., Li, W., Li, B., Wu, K., Hung, H., Lin, X., & Jiang, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201802452 · Cited by 97
Joh, D. Y., Zimmers, Z. A., Avlani, M., Heggestad, J. T., Aydın, H. B., Ganson, N. J., Kumar, S., Fontes, C. M., Achar, R. K., Hershfield, M. S., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801177 · Cited by 96
Chen, W.-A., Chang, D.-Y., Chen, B., Lin, Y., Barenholz, Y., & Roffler, S. R. (2023) · ACS Nano · doi:10.1021/acsnano.2c12193 · Cited by 105
Carreño, J. M., Singh, G., Tcheou, J., Srivastava, K., Gleason, C., Muramatsu, H., Desai, P., Aberg, J. A., Miller, R. L., study group, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.024 · Cited by 91
“369 Differential immunogenicity of PEG molecules containing a methoxy (mPEG), hydroxy (H)-PEG) 370 or t-butoxy (t-BuO-PEG) distal terminal groups has been described, with mPEG being more prone 371 to induce specific responses against this terminal group (31).”
BackgroundShimizu, T., Lila, A. S. A., Fujita, R., Awata, M., Kawanishi, M., Hashimoto, Y., Okuhira, K., Ishima, Y., & Ishida, T. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.02.019 · Cited by 95
Polypeptides–Drug Conjugates for Anticancer Therapy
Zhang, Y. X., He, P., Zhang, P., Yi, X., Xiao, C., & Chen, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001974 · Cited by 80
d’Avanzo, N., Celia, C., Barone, A., Carafa, M., Marzio, L. D., Santos, H. A., & Fresta, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900170 · Cited by 88
Anti-PEG antibodies enriched in the protein corona of PEGylated nanocarriers impact the cell uptake
Deuker, M., Mailänder, V., Morsbach, S., & Landfester, K. (2023) · Nanoscale Horizons · doi:10.1039/d3nh00198a · Cited by 84
Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies
Haddad, H. F., Burke, J. A., Scott, E. A., & Ameer, G. A. (2021) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-021-00198-y · Cited by 83
Striving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol
Bento, C., Katz, M., Santos, M. M. M., & Afonso, C. A. M. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00428 · Cited by 89
Özer, İ., Kelly, G., Gu, R., Li, X., Zakharov, N., Sirohi, P., Nair, S. K., Collier, J. H., Hershfield, M. S., Hucknall, A., et al. (2022) · Advanced Science · doi:10.1002/advs.202103672 · Cited by 77
Groh, K. J., Geueke, B., & Muncke, J. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.08.023 · Cited by 72
“Polyethylene glycol (PEG) presents another example of a synthetic polymer with potential antigenic and immunogenic properties (Kierstead et al., 2015; Sherman et al., 2012), although disputed (Schellekens et al., 2013).”
BackgroundWan, X., Zhang, J., Yu, W., Shen, L., Ji, S., & Hu, T. (2016) · Process Biochemistry · doi:10.1016/j.procbio.2016.09.029 · Cited by 57
Biophysical, biopharmaceutical and toxicological significance of biomedical nanoparticles
Aula, S., Lakkireddy, S., Jamil, K., Kapley, A., Swamy, A. V. N., & Reddy, L. H. (2015) · RSC Advances · doi:10.1039/c5ra05889a · Cited by 62
Chen, J., Rizvi, A., Patterson, J. P., & Hawker, C. J. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07859 · Cited by 59
Gaballa, S. A., Shimizu, T., Ando, H., Takata, H., Emam, S. E., Ramadan, E., Naguib, Y. W., Mady, F. M., Khaled, K. A., & Ishida, T. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.001 · Cited by 68
Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo
Lim, S. I., Hahn, Y. S., & Kwon, I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.004 · Cited by 50
“Emerging concerns over immunogenicity of the methoxy terminus of PEG should not be overlooked [75,76].”
BackgroundShin, K., Suh, H., Grundler, J., Lynn, A. Y., Pothupitiya, J. U., Moscato, Z. M., Reschke, M., Bracaglia, L. G., Piotrowski-Daspit, A. S., & Saltzman, W. M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121676 · Cited by 50
Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation
Han, Y., Yuan, Z., Zhang, P., & Jiang, S. (2018) · Chemical Science · doi:10.1039/c8sc01777h · Cited by 55
Yu, Y., Xu, W., Huang, X., Xu, X., Qiao, R., Li, Y., Han, F. Y., Peng, H., Davis, T. P., Fu, C., et al. (2020) · ACS Macro Letters · doi:10.1021/acsmacrolett.0c00291 · Cited by 51
Polyethylene glycol: Properties, applications, and challenges
Gaballa, S. A., Naguib, Y. W., Mady, F. M., & Khaled, K. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.241685.1205 · Cited by 77
“The order of immunogenicity against the administered PEGylated proteins was as follows Bu-PEG > mPEG > OH-PEG (75).”
BackgroundInfluentialDrug and protein delivery by polymer conjugation
Grigoletto, A., Maso, K., Mero, A., Rosato, A., Schiavon, O., & Pasut, G. (2015) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2015.08.006 · Cited by 45
Hashimoto, Y., Shimizu, T., Mima, Y., Lila, A. S. A., Ishida, T., & Kiwada, H. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.03.002 · Cited by 47
Ehlinger, C., Spear, N., Doddareddy, R., Shankar, G., & Schantz, A. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.112669 · Cited by 44
Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma
Fang, J., Beland, F. A., Tang, Y., & Roffler, S. R. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.12.022 · Cited by 47
“Since Western blotting generally requires a high quality of antibody with the appropriate concentration [31], the low concentration of anti-PEG antibodies may be a factor leading to the discrepancy in the detection of the low-level anti-PEG antibodies using a flow cytometry assay and Western blotting of purified plasm…”
Clinical translational barriers against nanoparticle-based imaging agents
Jin, R., Fu, X., Pu, Y., Fu, S., Liang, H., Yang, L., Nie, Y., & Ai, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114587 · Cited by 46
Ruderfer, I., Shulman, A., Kizhner, T. A., Azulay, Y., Nataf, Y., Tekoah, Y., & Shaaltiel, Y. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00133 · Cited by 41
Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture
Lin, Y., Chen, B., Tran, T. T. M., Chang, T.-C., Al‐Qaisi, T. S., & Roffler, S. R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.021 · Cited by 44
Immune response against the biomaterials used in 3D bioprinting of organs
Elalouf, A. (2021) · Transplant Immunology · doi:10.1016/j.trim.2021.101446 · Cited by 43
Chan, L. J., Bulitta, J. B., Ascher, D. B., Haynes, J. M., McLeod, V. M., Porter, C. J. H., Williams, C. C., & Kaminskas, L. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5006189 · Cited by 40
Sylvestre, M., Lv, S., Yang, L. F., Luera, N., Peeler, D. J., Chen, B., Roffler, S. R., & Pun, S. H. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.015 · Cited by 43
Luppi, B. T., Primrose, W. L., & Hudson, Z. M. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202400712 · Cited by 40
Reddy, L. H., & Bazile, D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.08.012 · Cited by 44
“In a recent report [257] related to the PEG-protein conjugates, it has been shown that the terminal functional group of the PEG had an influence on the affinity and selectivity of the binding of anti-PEG antibodies onto the PEG-conjugates.”
Nguyen, M.-T. T., Shih, Y.-C., Lin, M.-H., Roffler, S. R., Hsiao, C.-Y., Cheng, T., Lin, W.-W., Lin, E., Jong, Y., Chang, C., et al. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00709-0 · Cited by 39
Zhang, P., Sun, F., Hung, H., Jain, P. R., Leger, K. J., & Jiang, S. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02447 · Cited by 38
Zai, W., Yang, M. J., Jiang, K., Guan, J., Wang, H., Hu, K., Huang, C. R., Chen, J., Fu, W. E., Zhan, C., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01871-8 · Cited by 44
“22 Moreover, our group recently uncovered that hydroxy-PEG has weaker anti-genicity than methoxy-PEG.”
BackgroundPoppenborg, S. M., Wittmann, J., Walther, W., Brandenburg, G., Krähmer, R., Baumgart, J., & Leenders, F. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.06.007 · Cited by 35
Lam, J. H., Shivhare, D., Chia, T. W., Chew, S. L., Sinsinbar, G., Aw, T. Y., Wong, S., Venkataraman, S., Lim, F. W. I., Vandepapelière, P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06350 · Cited by 33
Enzyme-Based Anti-Inflammatory Therapeutics for Inflammatory Diseases
Narayanan, K. B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050606 · Cited by 50
“Sherman et al. [141] demonstrated that PEG-protein conjugates synthesized us-ing monofunctionally activated hydroxy-PEG (HO-PEG) exhibited lower antigenicity and immunogenicity compared to their mPEG-conjugated counterparts, suggesting that the chemical structure of PEG plays a crucial role in…”
Zwitterionic Nanoconjugate Enables Safe and Efficient Lymphatic Drug Delivery
Li, B., Yuan, Z., He, Y., Hung, H., & Jiang, S. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c01713 · Cited by 33
Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
Zhao, L., Niu, J., Lin, H., Zhao, J., Liu, Y., Song, Z., Xiang, C., Wang, X., Yang, Y., Li, X., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.09.052 · Cited by 36
Malhotra, M., Tomaro-Duchesneau, C., Saha, S., & Prakash, S. (2013) · International Journal of Biomaterials · doi:10.1155/2013/252531 · Cited by 38
Therapeutic Oligonucleotides with Polyethylene Glycol Modifications
Winkler, J. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.94 · Cited by 28
Zwitterionic Polymer: A New Paradigm for Protein Conjugation beyond PEG
Zeng, Z., Chen, S., & Chen, Y. (2023) · ChemMedChem · doi:10.1002/cmdc.202300245 · Cited by 29
PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation
Gao, P. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.133 · Cited by 32
Mitigation of Hydrophobicity-Induced Immunotoxicity by Sugar Poly(orthoesters)
Maiti, S., Manna, S., Shen, J., Esser-Kahn, A. P., & Du, W. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b12205 · Cited by 25
Gonçalves, J., & Caliceti, P. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s481420 · Cited by 30
“Sherman et al (2012) demonstrated that hydroxy-PEG has a lower immunogenicity than mPEG derivatives of porcine uricase and other proteins.”
BackgroundZhang, Y., Hu, M., Xin, R., Xu, X., Zhang, Z., Peng, H., Cai, R., Chen, C., Whittaker, A. K., & Fu, C. (2025) · Polymer science & technology. · doi:10.1021/polymscitech.5c00084 · Cited by 25
Cross-Reactivity of Select PEG-Binding Antibodies to Other Polymers Containing a C-C-O Backbone
McCallen, J., Prybylski, J. P., Yang, Q., & Lai, S. K. (2017) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00147 · Cited by 27
Immunological responses to PEGylated proteins
Elsadek, N. E., Lila, A. S. A., & Ishida, T. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64081-9.00005-x · Cited by 34
Emerging trends of discrete Poly(ethylene glycol) in biomedical applications
Hu, J., & Liu, S. (2022) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2022.100419 · Cited by 28
Advancing mRNA vaccines for infectious diseases: key components, innovations, and clinical progress
Li, S., Zheng, L., Zhong, J., & Gao, X. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253009 · Cited by 24
“Methoxy-PEGylation (MeO-PEG) is widely applied in numerous marketed nanomedicines, including MeO-PEG-DMG and ALC-0159 [74,75].”
Better the devil you know than the devil you don’t — PEG challenges in nanomedicine
Dobrovolskaia, M. A. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01925-0 · Cited by 28
Adverse immunological responses against non-viral nanoparticle (NP) delivery systems in the lung
de Braganca, L., Ferguson, G. J., Santos, J. L., & Derrick, J. P. (2021) · Journal of Immunotoxicology · doi:10.1080/1547691x.2021.1902432 · Cited by 26
“…of anti-PEG antibodies is largely dictated by the terminal group of the PEG chain; substituting a methoxy terminal group with a hydroxyl terminal group can mitigate the anti-PEG antibody response, as the hydroxyl group is less antigenic and immunogenic (Sherman et al. 2012; Shimizu et al. 2018).”
BackgroundPEGylation and anti-PEG antibodies
Lila, A. S. A., Shimizu, T., & Ishida, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101750-0.00003-9 · Cited by 27
Dong, H., Mora, J. R., Brockus, C. L., Chilewski, S. D., Dodge, R. W., Merrifield, C., Dickerson, W. M., & Desilva, B. S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9799-4 · Cited by 21
“(14, 15) previously reported on the detrimental effects of such surfactants on the sensitivity of detection for anti-PEG antibodies.”
BackgroundImmunogenicity Risk Assessment for PEGylated Therapeutics
Mora, J. R., White, J. T., & DeWall, S. L. (2020) · The AAPS Journal · doi:10.1208/s12248-020-0420-0 · Cited by 25
“(51), is the hydrophobicity of the PEG and how it may influence immunogenicity incidence.”
BackgroundHow to solve the problem of hypersensitivity to asparaginase?
Pui, C., Liu, Y., & Relling, M. V. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26884 · Cited by 20
Gaballa, S. A., Shimizu, T., Takata, H., Ando, H., Ibrahim, M. A., Emam, S. E., Matsuo, N. C. A., Kim, Y., Naguib, Y. W., Mady, F. M., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00774 · Cited by 22
The Use of Lactose as an Alternative Coating for Nanoparticles
Betker, J. L., & Anchordoquy, T. J. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.01.019 · Cited by 19
Metadata
- Authors
- Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P.
- Affiliations
- Edison Pharmaceuticals (United States) (US)
- Corresponding author
- Sherman, Merry R.
- Venue
- Bioconjugate Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-03-07
- Volume
- 23
- Issue
- 3
- Pages
- 485-499
- ISSN
- 1043-1802 (ISSN-L)
- 1520-4812
- PMC
- PMC3309606
- OpenAlex
- W64311466
- Cited by
- 185
- References
- 53
- Citations by year
- 2026: 14 · 2025: 26 · 2024: 13 · 2023: 14 · 2022: 16 · 2021: 13 · 2020: 13 · 2019: 12 · 2018: 10 · 2017: 7 · 2016: 12 · 2015: 12 · 2014: 8 · 2013: 8 · 2012: 7
- FWCI
- 4.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioconjugate Chemistry (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- anti-PEG antibodies, PEGylation, immune response, antibody affinity, human serum albumin, interferon-alpha, uricase, superoxide dismutase
- MeSH terms
- Animals, Enzyme-Linked Immunosorbent Assay, Humans, Polyethylene Glycols, Proteins, Rabbits, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.